scispace - formally typeset
Journal ArticleDOI

Novel advancements in the management of hepatocellular carcinoma in 2008

Reads0
Chats0
TLDR
Sorafenib, a multikinase inhibitor, has shown survival benefits in patients at advanced stages of the disease, and proves that molecular targeted therapies can be effective in this otherwise chemo-resistant tumor.
About
This article is published in Journal of Hepatology.The article was published on 2008-01-01. It has received 804 citations till now. The article focuses on the topics: Sorafenib.

read more

Citations
More filters

EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
References
More filters
Journal ArticleDOI

Global cancer statistics

TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI

Global cancer statistics, 2002.

TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

TL;DR: Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis and after four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent.
Journal ArticleDOI

The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

TL;DR: Small-molecule therapeutics that block PI3K signalling might deal a severe blow to cancer cells by blocking many aspects of the tumour-cell phenotype.
Journal ArticleDOI

Management of hepatocellular carcinoma.

TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Related Papers (5)